NDA 214622 · Helsinn Hlthcare
Truseltiq
Infigratinib Phosphate · Oral
NovelAccelerated approvalPriority reviewOrphanDiscontinuedCDER novel approval, May 28, 2021: To treat cholangiocarcinoma whose disease meets certain criteria
Last checked: Nov 20, 2026Latest source record: May 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
May 28, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
32
5 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat cholangiocarcinoma whose disease meets certain criteria
Therapeutic areas: Oncology · Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 28, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
2 products under this application
- TRUSELTIQ · INFIGRATINIB PHOSPHATE 25MG · CAPSULE, ORAL · Discontinued
- TRUSELTIQ · INFIGRATINIB PHOSPHATE 100MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Infigratinib" as an intervention, any sponsor and status, largest first.
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitation
QED Therapeutics, a BridgeBio companyIndustry
NCT05145010 · 325 participants (planned) · Start Dec 6, 2021 · Primary completion Dec 1, 2031
Drug: Infigratinib; Infigratinib · For: Achondroplasia
Sites: Oakland, California; Aurora, Colorado; Wilmington, Delaware · 31 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01004224 · 208 participants · Start Dec 11, 2009 · Primary completion Oct 8, 2018
Drug: BGJ398 · For: Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3; Squamous Lung Cancer With FGFR1 Amplification; Bladder Cancer With FGFR3 Mutation or Fusion and 3 more
Sites: Duarte, California; Los Angeles, California; Aurora, Colorado · 50 sites in all
PfizerPfizer (PFE)
NCT02159066 · 158 participants · Start Jul 23, 2014 · Primary completion Jan 10, 2023
Drug: LGX818; MEK162 and 4 more · For: Melanoma
Sites: Los Angeles, California; New York, New York; Portland, Oregon · 32 sites in all
QED Therapeutics, a BridgeBio companyIndustry
NCT02150967 · 143 participants · Start Jul 23, 2014 · Primary completion Mar 1, 2021
Drug: BGJ398 (infigratinib) · For: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 37 sites in all
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitation
QED Therapeutics, a BridgeBio companyIndustry
NCT07393373 · 135 participants (planned) · Start Apr 23, 2026 · Primary completion May 31, 2036
Drug: Infigratinib · For: Hypochondroplasia
Sites: Oakland, California; Aurora, Colorado; Washington D.C., District of Columbia · 24 sites in all
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaPivotal-lookingCompleted
QED Therapeutics, a BridgeBio companyIndustry
NCT06164951 · 114 participants · Start Nov 10, 2023 · Primary completion Dec 18, 2025
Drug: Infigratinib 0.25 mg/kg/day; Placebo Comparator 0.25 mg/kg/day · For: Achondroplasia
Sites: San Francisco, California; Aurora, Colorado; Baltimore, Maryland · 27 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02160041 · 84 participants · Start Jul 24, 2014 · Primary completion Apr 30, 2018
Drug: BGJ398 · For: Solid Tumor; Hematologic Malignancies
Sites: Birmingham, Alabama; Oceanside, California; San Francisco, California · 56 sites in all
QED Therapeutics, a BridgeBio companyIndustry
NCT04265651 · 84 participants · Start Mar 10, 2020 · Primary completion Oct 21, 2024
Drug: Infigratinib 0.016 mg/kg; Infigratinib 0.032 mg/kg and 3 more · For: Achondroplasia
Sites: Oakland, California; Wilmington, Delaware; Baltimore, Maryland · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Infigratinib Therapy in Children with Achondroplasia.
Savarirayan R, De Bergua JM, Arundel P, et al. · N Engl J Med 2025 · Multicenter Study, Clinical Trial, Phase II
- Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.
Savarirayan R, Hoover-Fong J, Irving M, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, et al. · Clin Cancer Res 2022 · Clinical Trial, Phase II, Multicenter Study
- Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor.
Magone MT, Hartley IR, Fitzgibbon E, et al. · Ophthalmology 2021 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.
Makawita S, K Abou-Alfa G, Roychowdhury S, et al. · Future Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.
Yuan J, Shen L, Liu TS, et al. · Clin Transl Sci 2024 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Helsinn Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.